

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



*I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on May 15, 2002.*

RECEIVED

Elise D. Bray

JUN 03 2002

TECH CENTER 1600/2900

Applicant : Wolfgang Wuttke, et al.  
Application No. : 09/646,740  
Filed : September 18, 2000  
Title : UTILIZATION OF EXTRACTS FROM IRIS PLANTS, CIMICIFUGA  
RACEMOSA AND TECTORIGENIN AS AN ESTROGEN-LIKE  
ORGAN-SELECTIVE MEDICAMENT WITHOUT UTEROTROPIC  
EFFECTS  
  
Grp./Div. : 1651  
Examiner : Michele C. Flood  
  
Docket No. : 43687/KMO/W338

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Post Office Box 7068  
Pasadena, CA 91109-7068  
May 15, 2002

Commissioner:

In response to the Office action of November 15, 2001, please amend the above-identified application as follows:

**In the Claims:**

Please amend claims 17 and 18 and add new claim 26. All of pending claims 17 to 26 follow.

C1  
17. (Amended) A method for producing an estrogen-type effect in a patient without causing a substantial uterotrophic effect, the method comprising administering to the patient an effective amount of a medicament comprising an extract from an Iridaceae plant, wherein the extract is selected from the group consisting of *Belamcanda chinensis*, *Iris Germanica*, *Iris tectorum*, *Iris Illyrica*, and *Iris dichotoma*,